Evidence map›Paper›PMID 39027207›Full record

ArticleJournal of advanced periodontology & implant dentistry2024

Comparison of salivary beta-defensin-1 levels in patients with periodontitis before and after phase I periodontal therapy.

Somaye Ansari Moghadam, Sina Pishadast, Leila Gholami, Ebrahim Alijani, Alireza Ansari Moghadam, Mahdi Hadilou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of advanced periodontology & implant dentistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Somaye Ansari MoghadamDepartment of Periodontology, Oral and Dental Disease Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.ORCID https://orcid.org/0000-0002-6072-7055
Sina PishadastOral and Dental Disease Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
Leila GholamiDepartment of Oral Biological and Medical Sciences, Faculty of Dentistry, University of British Columbia, Vancouver, Canada.
Ebrahim AlijaniDepartment of Clinical Immunology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
Alireza Ansari MoghadamDepartment of Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
Mahdi HadilouFaculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0001-9018-3450

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study compared human β-defensin 1 ( Methods: This controlled before-and-after study included 16 patients in the intervention group and 28 participants in the control group. Patients in the intervention group had stage 3 grade B periodontitis with no systemic diseases and had not taken any medications in the last six months. The control group included participants with healthy periodontium. Before and after phase I periodontal therapy, salivary samples were collected from the intervention group. ELISA was used to measure hBD-1 levels. Results: Salivary levels of hBD-1 decreased after phase I periodontal treatment in periodontitis patients, approaching those in healthy individuals. However, this reduction was not statistically significant ( Conclusion: The current study demonstrated promising results concerning a probable link between hBD-1 and periodontitis. However, more research with sufficiently large sample sizes and more robust study designs is necessary.

Indexed as

Beta-defensinsChronic periodontitisEnzyme-linked immunosorbent assayRoot planing

Identifiers

PMID39027207
PMCPMC11252152

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.